Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$39.15M$39.15M+11.2% vs Q2 2018 Net Income-$14.62M-$14.62MN/M vs Q2 2018 EPS Diluted-$0.10-$0.10N/M vs Q2 2018 Gross Profit$3,883,000+6.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$24,786,000N/M Free Cash Flowderived-$26,154,000N/M Margins · derivedGross margin9.9%−0.4 pt vs Q2 2018
Operating margin-35.7%+21.3 pt vs Q2 2018
Net margin-37.4%+27.7 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 6, 2019 · 37 d after period end